{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-22607","upperLimit":"0","value":"-20"},{"groupId":"OG001","lowerLimit":"-3308","upperLimit":"0","value":"-25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"End of Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-28176","upperLimit":"0","value":"-87"},{"groupId":"OG001","lowerLimit":"-1962","upperLimit":"4.5","value":"-22.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"title":"At treatment discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-24703","upperLimit":"0","value":"-20"},{"groupId":"OG001","lowerLimit":"-3258","upperLimit":"0","value":"-18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"6-month follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-22656","upperLimit":"20","value":"0"},{"groupId":"OG001","lowerLimit":"-3361","upperLimit":"0","value":"-20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"12-month follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle)","id":"OG000","title":"Phase II: VR-DA-EPOCH"},{"description":"Arm B (DA-R-EPOCH), which is the same treatment as Arm A, but without Vorinostat","id":"OG001","title":"Phase II: DA-R-EPOCH"}],"paramType":"MEDIAN","populationDescription":"Phase II participants who returned for follow-up with evaluable data.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 months","title":"Changes in Human Immunodeficiency Virus (HIV) Viral Load","type":"SECONDARY","unitOfMeasure":"median change in copies per mL"}